metricas
covid
Buscar en
Revista Colombiana de Psiquiatría
Toda la web
Inicio Revista Colombiana de Psiquiatría Rabdomiolisis y falla renal aguda en un paciente con trastorno depresivo recurre...
Información de la revista
Vol. 39. Núm. 3.
Páginas 617-623 (septiembre 2010)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 39. Núm. 3.
Páginas 617-623 (septiembre 2010)
Reporte de caso
Acceso a texto completo
Rabdomiolisis y falla renal aguda en un paciente con trastorno depresivo recurrente tratado con escitalopram y quetiapina
Rhabdomyolysis and Acute Renal Failure in a Recurrent Depressive Patient Treated with Escitalopram and Quetiapine: Case Report
Visitas
2510
Luis Orozco-Cabal1, Carlos Gómez-Restrepo2,
Autor para correspondencia
cgomez@javeriana.edu.co

Correspondencia: Carlos Gómez-Restrepo, Departamento de Epidemiología Clínica y Bioestadística, Pontificia Universidad Javeriana, Carrera 7 No. 40-62, Bogotá, Colombia
, Martha Patricia Rodríguez-Sánchez3
1 Médico, doctor en neurociencias, residente de Psiquiatría, Departamento de Psiquiatría y Salud Mental, Facultad de Medicina, Pontifica Universidad Javeriana. Bogotá, Colombia
2 Médico psiquiatra, psicoanalista, MSc en Epidemiología Clínica. Profesor del Departamento de Psiquiatría y Salud Mental y director del Departamento de Epidemiología Clínica y Bioestadística, de la Facultad de Medicina de la Pontificia Universidad Javeriana. Bogotá, Colombia
3 Médica internista, nefróloga. Unidad de Nefrología, profesora asistente, Departamento de Medicina Interna de la Facultad de Medicina de la Pontificia Universidad Javeriana. Bogotá, Colombia
Este artículo ha recibido
Información del artículo
Resumen
Objetivo

Describir un caso de rabdomiolisis y falla renal aguda asociado a la administración de quetiapina y escitalopram en un adulto joven en tratamiento por depresión recurrente.

Métodos

Descripción detallada del paciente y de su enfermedad actual, y revisión no sistemática de la literatura relevante.

Resultados

Sujeto de 35 años con antecedentes de trastorno depresivo para el cual recibía escitalopram y quetiapina; presenta síntomas consistentes con rabdomiolisis y falla renal aguda luego de ingerir una sobredosis (900 mg) de quetiapina. La quetiapina y otros antipsicóticos han sido asociados a rabdomiolisis con o sin falla renal aguda. Igualmente, antidepresivos han sido asociados con episodios similares. El mecanismo que media tal asociación no ha sido encontrado.

Conclusiones

Los antipsicóticos y los antidepresivos están asociados a rabdomiolisis en individuos con susceptibilidad biológica. Los efectos tóxicos de la serotonina pueden estar involucrados en tal asociación. Lo anterior obliga a su empleo cuidadoso en pacientes en riesgo de hiperfunción serotoninérgica.

Palabras clave:
medicamentos antipsicóticos
mioglobinuria
serotonina
Abstract
Objective

To describe a case of quetipiane- and escitalopram-associated rhabdomyolysis and secondary acute renal failure in a young adult suffering from recurrent depression.

Method

detailed clinical description of the subject's case and relevant literature was reviewed.

Results

A 35-year old male suffering from recurrent mayor depression treated with quetiapine and escitalopram, developed rhabdomyolysis and acute renal failure after ingesting an overdose of quetiapine (900 mg). Quetiapine and other antipsychotics have been related with rhabdomyolysis with or without renal failure in association or not with neuroleptic malignant syndromes. Similarly, antidepressant medications, specially venlafaxine but not escitalopram, have been associated with rhabdomyolysis. However, the exact mechanisms involved in this association have are not clear.

Conclusions

Antipsychotic and antidepressant medications have been associated with rhabdomyolysis in vulnerable subjects. Serotonin-mediated toxicity has been proposed as a plausible etiological factor in these cases. Thus, psychotropic medications involving this neurotransmitter should be used cautiously in subjects at risk for serotonin hyperactivity.

Key words:
Antipsychotic agents
myoglobinuria
serotonin
El Texto completo está disponible en PDF
Referencias
[1]
KJ Ressler, HS Mayberg.
Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic.
Nat Neurosci, 10 (2007), pp. 1116-1124
[2]
SN Ghaemi.
Why antidepressants are not antidepressants: STEP-BD, STAR*D, and the return of neurotic depression.
Bipolar Disord, 10 (2008), pp. 957-968
[3]
Global burden of disease and risk factors,
[4]
M Fava, AJ Rush.
Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice.
Psychother Psychosom, 75 (2006), pp. 139-153
[5]
C Tranulis, L Skalli, P Lalonde, L Nicole, E Stip.
Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature.
Drug Saf, 31 (2008), pp. 7-20
[6]
X Bosch, E Poch, JM Grau.
Rhabdomyolysis and acute kidney injury.
N Engl J Med, 361 (2009), pp. 62-72
[7]
SB Stillwell.
Quick critical care reference, 3rd ed., Mosby, (1998),
[8]
G Melli, V Chaudhry, DR Cornblath.
Rhabdomyolysis: an evaluation of 475 hospitalized patients.
Medicine (Baltimore), 84 (2005), pp. 377-385
[9]
JR Blanco, M Zabalza, J Salcedo, L Echeverria, A García, M Vallejo.
Rhabdomyolysis on infectious and noninfectious causes.
South Med J, 95 (2002), pp. 542-544
[10]
A Koffler, RM Friedler, SG Massry.
Acute renal failure due to nontraumatic rhabdomyolysis.
Ann Intern Med, 85 (1976), pp. 23-28
[11]
RA Grossman, RW Hamilton, BM Morse, AS Penn, M Goldberg.
Nontraumatic rhabdomyolysis and acute renal failure.
N Eng J Med, 291 (1974), pp. 807-811
[12]
MA Marinella.
Rhabdomyolysis associated with haloperidol without evidence of NMS.
Ann Pharmacother, 31 (1997), pp. 927-928
[13]
CJ Rosebraugh, DA Flockhart, SU Yasuda, RL Woosley.
Olanzapine-induced rhabdomyolysis.
Ann Pharmacother, 35 (2001), pp. 1020-1023
[14]
SN Scelsa, DM Simpson, HL McQuistion, A Fineman, K Ault, B Reichler.
Clozapine-induced myotoxicity in patients with chronic psychotic disorders.
Neurology, 47 (1996), pp. 1518-1523
[15]
JL Patier, F Ferrere, MA Moreno-Cobo, A Echaniz.
[Rhabdomyolysis caused by the association of simvastatin and risperidone].
Med Clin (Barc), 129 (2007), pp. 439
[16]
C Stephani, C Trenkwalder.
Rhabdomyolysis after low-dose quetiapine in a patient with Parkinson's disease with drug-induced psychosis: a case report.
Mov Disord, 25 (2010), pp. 782-783
[17]
BK Plesnicar, JK Lasic, A Plesnicar.
Quetiapine and elevated creatine phosphokinase (CK).
Pharmacopsychiatry, 40 (2007), pp. 203-204
[18]
H Himmerich, M Ehrlinger, M Hackenberg, B Löhr, T Nickel.
Possible case of quetiapine-induced rhabdomyolysis in a patient with depression treated with fluoxetine.
J Clin Psychopharmacol, 26 (2006), pp. 676-677
[19]
RP Smith, BN Puckett, J Crawford, RL Elliott.
Quetiapine overdose and severe rhabdomyolysis.
J Clin Psychopharmacol, 24 (2004), pp. 343
[20]
LA Linares, BA Golomb, JA Jaojoco, H Sikand, PS Phillips.
The modern spectrum of rhabdomyolysis: drug toxicity revealed by creatine kinase screening.
Curr Drug Saf, 4 (2009), pp. 181-187
[21]
SH Yang, MJ McNeely.
Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone.
Am J Psychiatry, 159 (2002), pp. 1435
[22]
AN Zaidi.
Rhabdomyolysis after correction of hyponatremia in psychogenic polydipsia possibly complicated by ziprasidone.
Ann Pharmacother, 39 (2005), pp. 1726-1731
[23]
C Akkaya, A Sarandol, EY Sivrioglu, Z Kotan, S Kirli.
A patient using ziprasidone with polydipsia, seizure, hyponatremia and rhabdomyolysis.
Prog Neuropsychopharmacol Biol Psychiatry, 30 (2006), pp. 1535-1538
[24]
HY Meltzer, PA Cola, M Parsa.
Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment.
Neuropsychopharmacology, 15 (1996), pp. 395-405
[25]
H Narukami, K Yoshioka, J Zhao, T Miike.
Experimental serotonin myopathy as an animal model of muscle degeneration and regeneration in muscular dystrophy.
Acta Neuropathol, 81 (1991), pp. 510-516
[26]
AD Wilson, C Howell, WS Waring.
Venlafaxine ingestion is associated with rhabdomyolysis in adults: a case series.
J Toxicol Sci, 32 (2007), pp. 97-101
[27]
RJ Flanagan.
Fatal toxicity of drugs used in psychiatry.
Hum Psychopharmacol, 23 Suppl 1 (2008), pp. 43-51
[28]
N Bonetto, L Santelli, L Battistin, A Cagnin.
Serotonin syndrome and rhabdomyolysis induced by concomitant use of triptans, fluoxetine and hypericum.
Cephalalgia, 27 (2007), pp. 1421-1423
[29]
M Portilla-Botelho, J Ortega-Carnicer, ML Gómez-Grande, C Martín-Rodríguez.
[Paroxetine-induced severe hyponatremic rhabdomyolysis].
Med Intensiva, 32 (2008), pp. 365-366
[30]
P Gareri, C Segura-García, P De Fazio, S De Fazio, G De Sarro.
Sertraline-induced rhabdomyolysis in an elderly patient with dementia and comorbidities.
Ann Pharmacother, 43 (2009), pp. 1354-1359

Conflictos de interés: Carlos Gómez Restrepo y Martha Patricia Rodríguez-Sánchez no reportan conflictos de interés en este artículo. Luis Orozco-Cabal es consultor médico para Tecnofarma S. A.

Copyright © 2010. Asociación Colombiana de Psiquiatría
Opciones de artículo